US EditionPublished • loading... • Updated
Why the return of M&A to the biotech sector is a big deal |International Biotechnology Trust
Summary by Wealth DFM
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Why the return of M&A to the biotech sector is a big deal |International Biotechnology Trust
By Ailsa Craig and Marek Poszepczynski, portfolio managers of International Biotechnology Trust (IBT), for Wealth DFM After years of subdued deal-making, biotechnology M&A is firmly back — and its return carries major implications for investors. With big pharma facing looming patent cliffs and leaning ever more heavily on biotech innovation, revived acquisition activity is once again proving a critical engine of value creation. From pre-bid rall…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
